Novartis' CAR-T fails to help a vulnerable group of NHL patients — quashing hope of moving up lines of treatment
Novartis’ efforts to move its CAR-T into earlier lines of treatment have hit a brick wall.
Kymriah, its pioneering CD19-targeting therapy, has failed to bend the curve on event-free survival for patients with second-line aggressive B-cell non-Hodgkin lymphoma when compared with standard of care. While the treatment arm was given infusions of engineered T cells, the SOC group had salvage chemotherapy followed — in responding patients — by high-dose chemotherapy and stem cell transplant.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.